Top Cited Articles

In celebration of the inclusion of ESMO Open in the Emerging-Sources Citation Index (ESCI), with content appearing in Web-of-Science, we wanted to highlight some of the top cited articles published in the journal.

ESMO Open is also indexed in PubMed Central, Scopus and the DOAJ.

Mechanisms of resistance to EGFR-targeted drugs: lung cancer
Morgillo F, Della Corte CM, Fasano M, et al
10.1136/esmoopen-2016-000060

NTRK gene fusions as novel targets of cancer therapy across multiple tumour types
Amatu A, Sartore-Bianchi A, Siena S
10.1136/esmoopen-2015-000023

Biosimilars: a position paper of the European Society for Medical Oncology, with particular reference to oncology prescribers
Tabernero J, Vyas M, Giuliani R, et al
10.1136/esmoopen-2016-000142

Integrating next-generation sequencing into clinical oncology: strategies, promises and pitfalls
Horak P, Fröhling S, Glimm H
10.1136/esmoopen-2016-000094

Twenty years of anti-HER2 therapy-associated cardiotoxicity
Pondé NF, Lambertini M, de Azambuja E
10.1136/esmoopen-2016-000073

Therapeutic value of EGFR inhibition in CRC and NSCLC: 15 years of clinical evidence
Troiani T, Napolitano S, Della Corte CM, et al
10.1136/esmoopen-2016-000088

Cancer and liver cirrhosis: implications on prognosis and management
Pinter M, Trauner M, Peck-Radosavljevic M, et al
10.1136/esmoopen-2016-000042

ESMO / ASCO Recommendations for a Global Curriculum in Medical Oncology Edition 2016
Dittrich C, Kosty M, Jezdic S, et al
10.1136/esmoopen-2016-000097

Scoring of PD-L1 expression intensity on pulmonary adenocarcinomas and the correlations with clinicopathological factors
Igarashi T, Teramoto K, Ishida M, et al
10.1136/esmoopen-2016-000083

Recent advances in the biology of human circulating tumour cells and metastasis
Gkountela S, Szczerba B, Donato C, et al
10.1136/esmoopen-2016-000078

Mechanisms of action and rationale for the use of checkpoint inhibitors in cancer
Granier C, De Guillebon E, Blanc C, et al
10.1136/esmoopen-2017-000213

Tumour-infiltrating lymphocytes are correlated with higher expression levels of PD-1 and PD-L1 in early breast cancer
Kitano A, Ono M, Yoshida M, et al
10.1136/esmoopen-2016-000150

New treatment options for metastatic renal cell carcinoma
Rodriguez-Vida A, Hutson TE, Bellmunt J, et al
10.1136/esmoopen-2017-000185

Final results of the large-scale multinational trial PROFILE 1005: efficacy and safety of crizotinib in previously treated patients with advanced/metastatic ALK-positive non-small-cell lung cancer
Blackhall F, Ross Camidge D, Shaw AT, et al
10.1136/esmoopen-2017-000219

Cardiotoxicity of immune checkpoint inhibitors
Varricchi G, Galdiero MR, Marone G, et al
10.1136/esmoopen-2017-000247